Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04619004 · ClinicalTrials.gov registry record · Phase 2
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
A Phase 2 study of Non Small Cell Lung Cancer Metastatic and Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, sponsored by Daiichi Sankyo.
- Active
- Registry status
- Phase 2
- Development phase
- 277
- Enrollment target
- 20
- Study locations
NCT04619004 is a Phase 2 study of Non Small Cell Lung Cancer Metastatic and Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor that is active but no longer recruiting, run by Daiichi Sankyo. The registered enrollment target is 277 participants, below the 419-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT04619004, a Phase 2 study of Non Small Cell Lung Cancer Metastatic and Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor, is active but no longer recruiting, sponsored by Daiichi Sankyo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 277 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy-containing regimen.
Conditions Studied
Interventions
- DRUG Patritumab Deruxtecan (Fixed dose)
- DRUG Patritumab Deruxtecan (Up-Titration)
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- AdventHealth Orlando - Orlando
- Memorial Healthcare System - Pembroke Pines
- Florida Cancer Specialist-North - St. Petersburg
- Florida Cancer Specialists-Panhandle - Tallahassee
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
- Florida Cancer Specialists-East - West Palm Beach
California
- City of Hope - Duarte
- Moores Cancer Center at the UC San Diego Health - La Jolla
- Pacific Shores Medical Group - Long Beach
- USC Norris Comprehensive Cancer Center - Los Angeles
- University of California at Irvine - Orange
- Cedars Sinai - West Hollywood
Massachusetts
- Massachusetts General Hospital (MGH) - Hematology/Oncology - Boston
- Beth Israel Deaconess Medical Center, Harvard Medical School - Boston
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Colorado
- University of Colorado Denver - Anschutz Medical Campus - Aurora
Georgia
- Emory University - Dunwoody
Illinois
- Northwestern University - Chicago
Maryland
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2021-02-02 |
| Est. Completion | 2026-01-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04619004
The ClinicalTrials.gov registry entry for NCT04619004 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 419-participant average among 16 other Non Small Cell Lung Cancer Metastatic trials with a reported enrollment target (34% lower). The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non Small Cell Lung Cancer Metastatic appearing as the primary indexed condition, and to 2 interventions - of which Patritumab Deruxtecan (Fixed dose) is the first listed.
NCT04619004 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04619004 about?
NCT04619004 is a clinical study titled "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer". This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an activating EGFR mutation (exon 19 deletion or L858R) who have received and progressed on or after at least 1 EGFR TKI and 1 platinum-based chemotherapy...
What is the current status of trial NCT04619004?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 277 participants. The study started on 2021-02-02. Estimated completion is 2026-01-30.
What conditions does trial NCT04619004 study?
This clinical trial studies the following conditions: Non Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor.
What interventions are being tested in trial NCT04619004?
The interventions under investigation include: Patritumab Deruxtecan (Fixed dose) (DRUG), Patritumab Deruxtecan (Up-Titration) (DRUG).
Who is sponsoring clinical trial NCT04619004?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04619004 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non Small Cell Lung Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
ACTIVE NOT RECRUITING · Phase 2
-
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Non Small Cell Lung Cancer Metastatic
All registered trials for this condition
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.